WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

https://e-fundresearch.com/newscenter/167-comgest/artikel/46581-comgest-fondsmanager-chen-gelingt-china-im-jahr-des-hasen-das-comeback

Bank of America Securities Upgrades WuXi Biologics (02269 HK) to "Buy" and Raises Target Price to $114.6 http://www.aastocks.com/tc/stocks/news/aafn-con/now.1239489/latest-news

https://www.wuppertal.de/presse/meldungen/meldungen-2023/januar/102010100000464653.php

...After the completion, WuXi Biologics Holdings' shareholding will be reduced from about 15.14% to 13.82%, and it will continue to be the company's major shareholder. Allotment shareholders promise a 3-month lock-up period. Li Ge, chairman and non-executive director of the group, has about 19.66% of the control over WuXi Biologics Holdings and 55.03% of the votes at the general meeting of shareholders. WuXi Biologics Holdings holds about 640 million shares of WuXi Biologics, accounting for about 15.14% of the total issued share capital of the company.

https://www.stheadline.com/finance-live/3189053/%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9%E5%A4%A7%E8%82%A1%E6%9D%B1%E6%8A%98%E8%AE%9339%E6%B8%9B%E6%8C%815600%E8%90%AC%E8%82%A1-%E5%A5%97398%E5%84%84%E5%85%83

Wuxi  Bio Dives 4% as Major Shareholder Ditches 1.3% Stake at Over 3.9% Discount http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1239413/company-news/HK6

Big Bank Rating | Goldman Sachs: Quoted from WuXi Biologics (2269 HK) that it will focus on increasing market share in the future and maintain a target price of HK$93 https://finance.sina.cn/hkstock/sckxjfx/2023-01-13/detail-imxzzrzh2340607.d.html?from=wap

Jefferies: Wuxi Bio's Production Capacity Rises Sharply Outside of CN, Ready for More Innovative Collaborations with Clients http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1238183/company-news/HK6

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1238118/company-news/HK6 Macquarie Upgrades WUXI BIO to Outperform, TP Lifted to $80

UBS Upbeat on Recovery Outlook of CN Healthcares in 2023; Top Picks Innovent Bio, Hygeia, Others http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1237870/popular-news/HK6 ... Looking ahead to 2023, UBS remained upbeat on the outlook of China’s healthcare sector, owing to the more predictable industry policies, improving fundamentals of companies and historically-low sector valuation.  ... ... The broker also preferred ...  WUXI BIO (02269 HK) ...

M  Stanley Latest List of Beneficiaries of Reopening (Table) http://www.aastocks.com/en/stocks/news/aafn-con/now.1237774/latest-news u.a. WUXI BIO (02269 HK)

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1236854/company-news/HK6 CLSA Stays Upbeat on CN Healthcare; Top Picks CSPC PHARMA, SINOPHARM, WUXI BIO etc.

Good News?

🎈

Mit einer Einschätzung zur WuXi im unteren Drittel: https://amp-news.cnyes.com/news/id/5053724

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers https://www.prnewswire.com/news-releases/wuxi-biologics-and-gsk-enter-into-license-agreement-on-multiple-novel-bi---multi-specific-t-cell-engagers-301713506.html • WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms • WuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net sales